AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma - Wikidata - thesis-toulmin - TriplyDB

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

http://www.wikidata.org/entity/Q28661371

about

A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma Estradiol differently affects melanin synthesis of malignant and normal melanocytes: a relationship with clock and clock-controlled genes.Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.C23 promotes tumorigenesis via suppressing p53 activity.Mcl-1 stabilization confers resistance to taxol in human gastric cancer.Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer.The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors.SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling AEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-κB pathway and predicts poor outcome of the patients

P2860

Q33415592-027CDFD6-2752-41AD-8524-441AB1337302 Q34957229-02ABBF05-220F-43D0-BB53-9297161E132E Q34990555-7018EE5C-78D8-40A4-B3FD-88FD4B642CFC Q36106321-ED5DCEAB-4F51-4A63-962A-D3BEBC4133D1 Q36288343-B5862DD8-038D-4FAC-9512-ED4B8B9AA050 Q37228217-3C739C0F-77D9-47C5-BE33-562F88099DDD Q38526844-5B883345-D85F-4510-BDA1-F07E0C5AAD63 Q42323430-C9C787EE-10F9-42D4-B6E6-02142F81C3E9 Q43637703-E484CE4A-76F2-4802-8760-AD57B427AB78 Q47136689-C8C2BD88-793A-4048-9FC1-9F76541BF4E7 Q47139368-2232197D-B441-4FF8-A588-24B66C77CDB8 Q48090844-196535E1-E42E-4CC0-A06C-DB8889FA738B Q52652154-78792226-A15A-4861-A7D9-9E0A30E0CD1C Q53082217-CE1D2F5C-9DA0-4133-BCC6-42C9242B0505 Q54976750-0B4D9656-7AD4-4BFD-A22E-992C233CC1DA Q57010854-141CC570-C79B-46AC-8DB4-714A5FB82B97 Q58790965-21A4E555-E40E-4EE9-9D3B-C4305B2B1BEB

P2860

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

http://www.wikidata.org/entity/Q28661371

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@ast

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@en

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@nl

type

label

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@ast

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@en

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@nl

prefLabel

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@ast

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@en

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@nl

P1433

Q28661371-2DAA4A38-AF64-4A78-AD3E-6B1C9F7A224A

P1476

Q28661371-9A087577-8876-4524-8593-617225A45CBD

P2093

Q28661371-4324293E-CA04-4A3B-9878-B1CDD515FFEB

Q28661371-6AF7FA49-53D3-49BA-82AF-10E68943311F

Q28661371-76356353-1D83-4C00-8632-10E3074FEC58

Q28661371-9E0BFEDB-DE72-40EA-AEA2-4DD806CA739F

Q28661371-EF58157C-9CD4-4571-8D10-B185C41713FB

P2860

Q28661371-03875AB9-0853-48C8-ACA0-2114EA83084A

Q28661371-03DAEFCD-AB57-4748-9F48-735EAA63ADB4

Q28661371-13F3B3BD-F0E2-4AB9-ACEC-7BAB24E4A5B4

Q28661371-162FAD33-5A70-4353-A552-A806830F89F2

Q28661371-19B152DB-619A-44C7-8360-8F20417CED62

Q28661371-2507BF0C-CF7B-4473-A92B-F03C7470B153

Q28661371-304ED502-D9C8-4782-B047-BE47B9CD7B17

Q28661371-335DBAC8-6A6B-4F1C-964B-41F6A7DF8E3D

Q28661371-380AEA19-7A7E-4251-B438-1D53270153B7

Q28661371-3FD454C6-F77F-45D8-B8F1-59C356939CD0

P304

Q28661371-1B64124A-D279-40DC-9B29-30BCEEADC86C

P31

Q28661371-CF4A71A9-8A1A-45A5-A1DC-EC8523CCD783

P356

Q28661371-A8B7A21C-D3C1-4066-9C71-C6BF49BF585A

P407

Q28661371-A533A4A4-0F74-4009-8296-A284D6A51894

P433

Q28661371-DFF7195B-11B1-4116-B606-A3319B651D63

P478

Q28661371-887A3F63-1D38-4A00-9982-60FE59D4DD8C

P50

Q28661371-1AE51AAE-59F4-4087-A1E2-B305DE904AAF

Q28661371-33DA799A-F0C8-438D-B7EA-2D276F35AC07

Q28661371-743A3651-509C-45EB-9BE0-0D4CC7BCE53F

Q28661371-F5ABF66A-FFC0-4CA1-9EE4-93BDD6FA49B0

P577

Q28661371-9A9780C6-8DB6-4EDC-94BA-05C0CC9CAA27

P5875

Q28661371-5C20C21D-3D9E-444D-87CA-2CD57996E549

P698

Q28661371-30E9BF7F-76C3-42F4-9A9F-9571D9A7D51B

P932

Q28661371-3C34A483-539E-40A4-B118-9DC4F5FA8CBA

P356

P1433

Cell Death and Disease

P1476

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

@en

P2093

C C Jiang

http://www.w3.org/2001/XMLSchema#string

M Wu

http://www.w3.org/2001/XMLSchema#string

Q Wu

http://www.w3.org/2001/XMLSchema#string

W Hu

http://www.w3.org/2001/XMLSchema#string

Y Mei

http://www.w3.org/2001/XMLSchema#string

P2860

Enzymic characterization of a novel member of the regulatory B-like carboxypeptidase with transcriptional repression function: stimulation of enzymic activity by its target DNA

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

P304

e914

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CDDIS.2013.441

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Scolyer

Georgina V. Long

P577

2013-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258348174

http://www.w3.org/2001/XMLSchema#string

P698

24201813

http://www.w3.org/2001/XMLSchema#string

P932

3847319

http://www.w3.org/2001/XMLSchema#string